These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26062595)

  • 21. Subgroups, treatment effects, and baseline risks: some lessons from major cardiovascular trials.
    Parker AB; Naylor CD
    Am Heart J; 2000 Jun; 139(6):952-61. PubMed ID: 10827374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic.
    Goland S; Naugolny V; Korbut Z; Rozen I; Caspi A; Malnick S
    Eur J Intern Med; 2011 Aug; 22(4):424-7. PubMed ID: 21767763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Appropriateness of spironolactone prescribing in heart failure patients: a population-based study.
    Ko DT; Juurlink DN; Mamdani MM; You JJ; Wang JT; Donovan LR; Tu JV
    J Card Fail; 2006 Apr; 12(3):205-10. PubMed ID: 16624686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperkalaemia in the age of aldosterone antagonism.
    Chapagain A; Ashman N
    QJM; 2012 Nov; 105(11):1049-57. PubMed ID: 22723454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identifying predictive markers for personalized treatment selection.
    Shen Y; Cai T
    Biometrics; 2016 Dec; 72(4):1017-1025. PubMed ID: 26999054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Study of the month. The RALES study (randomized aldactone evaluation study].
    Kulbertus H
    Rev Med Liege; 1999 Sep; 54(9):770-2. PubMed ID: 10589274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simple subgroup approximations to optimal treatment regimes from randomized clinical trial data.
    Foster JC; Taylor JM; Kaciroti N; Nan B
    Biostatistics; 2015 Apr; 16(2):368-82. PubMed ID: 25398774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of subgroups with differential treatment effects for longitudinal and multiresponse variables.
    Loh WY; Fu H; Man M; Champion V; Yu M
    Stat Med; 2016 Nov; 35(26):4837-4855. PubMed ID: 27346729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Bayesian approach to subgroup identification.
    Berger JO; Wang X; Shen L
    J Biopharm Stat; 2014; 24(1):110-29. PubMed ID: 24392981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiplicity issues in exploratory subgroup analysis.
    Lipkovich I; Dmitrienko A; Muysers C; Ratitch B
    J Biopharm Stat; 2018; 28(1):63-81. PubMed ID: 29173045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spironolactone for heart failure.
    Med Lett Drugs Ther; 1999 Sep; 41(1061):81-2. PubMed ID: 10505071
    [No Abstract]   [Full Text] [Related]  

  • 32. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study.
    Lund LH; Svennblad B; Melhus H; Hallberg P; Dahlström U; Edner M
    Circ Heart Fail; 2013 Mar; 6(2):174-83. PubMed ID: 23386667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Diuretic therapy in congestive heart failure--new views on spironolactone therapy].
    Haller C
    Ther Umsch; 2000 Jun; 57(6):374-9. PubMed ID: 10894022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort.
    Abbas S; Ihle P; Harder S; Schubert I
    Pharmacoepidemiol Drug Saf; 2015 Apr; 24(4):406-13. PubMed ID: 25683504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adaptive covariate adjustment in clinical trials.
    Wang SJ; Hung HM
    J Biopharm Stat; 2005; 15(4):605-11. PubMed ID: 16022166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spironolactone use in patients with heart failure.
    Trujillo JM; Gonyeau MJ; DiVall MV; Alexander SL
    J Clin Pharm Ther; 2004 Apr; 29(2):165-70. PubMed ID: 15068406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Valid randomization-based p-values for partially post hoc subgroup analyses.
    Lee JJ; Rubin DB
    Stat Med; 2015 Oct; 34(24):3214-22. PubMed ID: 25959735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Adaptation of guidelines for the treatment of chronic heart failure in a specialized heart failure clinic].
    Pölzl G; Gouya G; Hügel H; Frick M; Ulmer H; Pachinger O
    Wien Klin Wochenschr; 2002 Oct; 114(19-20):833-9. PubMed ID: 12503474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.